Sentia Medical Sciences

April 26, 2022
img: Featured

In April 2021, Neurocrine Biosciences entered into a research collaboration with Sentia Medical Sciences focused on discovering novel, long-acting coritcotropin-releasing factor (CRF) receptor antagonist peptide therapeutics. The collaboration leverages Sentia Medical Sciences’ proprietary peptide-based platform and our drug development expertise in CRF biology to develop and commercialize medicines with the potential to treat a variety of hypothalamic-pituitary-adrenal axis modulated diseases.